English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 1 August 2018, 18:35 HKT/SGT
Share:
Ascletis' NDA for Its All-oral HCV Treatment Accepted by CFDA

Hangzhou and Shaoxing, China , Aug 1, 2018 - (ACN Newswire) - Ascletis announced today it has received the acceptance letter from the China Food and Drug Administration (CFDA) for Ravidasvir (RDV) new drug application (NDA). Ravidasvir in combination with Ganovo (RDV/DNV Regimen) is the first all-oral interferon-free HCV regimen developed by a domestic company in China. Phase II/III clinical trial has shown that RDV/DNV Regimen demonstrated a cure rate of 99 % ( SVR12) with a short treatment duration of 12 weeks in genotype 1 patients. In patients with baseline NS5A resistance mutations, RDV/DNV Regimen demonstrated a cure rate of 100% (SVR12).

"Ascletis was successfully listed this morning on Hong Kong Exchange as the first ever pre-revenue biotech. The NDA for our all-oral HCV regimen was accepted by CFDA in the afternoon." Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO, commented, "Two significant accomplishments on the same day reflect our unremitting effort to provide affordable and effective HCV cures to the patients and to fulfill our commitment to the investors."

Ganovo Regimen, Ascletis' first breakthrough HCV regimen, was approved on June 8 and launched on June 27, 19 days after the approval. The acceptance of the NDA for its all-oral HCV regimen enables Ascletis soon to provide two HCV treatment options for Chinese patients, strengthening its leading position in China's HCV field.


Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019   
Sept 18, 2019 20:40 HKT/SGT
Mitsubishi Motors Hosts World Debuts of Small Electric SUV Concept Car at 46th Tokyo Motor Show 2019   
Sept 18, 2019 20:31 HKT/SGT
KDDI Joins Merpay, LINE Pay, and NTT DOCOMO's Merchant Alliance "Mobile Payment Alliance (MoPA)"  
Sept 18, 2019 20:19 HKT/SGT
DOCOMO to Commence Deployment of World's First 4G/5G Multi-vendor Radio Access Network Conforming to O-RAN Specifications  
Sept 18, 2019 14:12 HKT/SGT
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma  
Sept 18, 2019 13:58 HKT/SGT
MHI-MME to Take Over Production of MET Turbochargers  
Sept 18, 2019 13:46 HKT/SGT
KAHRAMAA, QEWC and MHPS Sign MOU on Internship Program for Young Qatari Engineers  
Sept 18, 2019 13:41 HKT/SGT
Toyota Installs Stationary Fuel Cell Generator Based on the Mirai FC System at its Honsha Plant in Japan  
Sept 18, 2019 12:34 HKT/SGT
Fujitsu Develops Digitization Technology to Quantify Various Walking Characteristics Resulting from Diseases  
Sept 18, 2019 10:30 HKT/SGT
Toyota Injects $391 Million New Investment in its San Antonio Assembly Plant  
Sept 18, 2019 06:54 HKT/SGT
More Press release >>
 Events:
More events >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575